Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07421778
PHASE1

A Multiple Ascending Dose Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants

Sponsor: QurAlis Corporation

View on ClinicalTrials.gov

Summary

QRL-101-08 is a multiple ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of a novel formulation of QRL-101 in healthy participants.

Official title: A Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel Formulation of QRL-101 in Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

48

Start Date

2026-02-02

Completion Date

2026-08-31

Last Updated

2026-02-19

Healthy Volunteers

Yes

Interventions

DRUG

QRL-101

Multiple-ascending doses of QRL-101 will be orally administered to healthy participants.

DRUG

Placebo

Multiple-ascending doses of comparator placebo will be administered orally to healthy participants.

Locations (1)

ICON plc.

Groningen, Netherlands